RT Journal Article
SR Electronic
T1 New insights on the genetic etiology of Alzheimer’s and related dementia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.01.20200659
DO 10.1101/2020.10.01.20200659
A1 Céline Bellenguez
A1 Fahri Küçükali
A1 Iris Jansen
A1 Victor Andrade
A1 Sonia Moreno-Grau
A1 Najaf Amin
A1 Adam C. Naj
A1 Benjamin Grenier-Boley
A1 Rafael Campos-Martin
A1 Peter A. Holmans
A1 Anne Boland
A1 Luca Kleineidam
A1 Vincent Damotte
A1 Sven J. van der Lee
A1 Teemu Kuulasmaa
A1 Qiong Yang
A1 Itziar de Rojas
A1 Joshua C. Bis
A1 Amber Yaqub
A1 Ivana Prokic
A1 Marcos R Costa
A1 Julien Chapuis
A1 Shahzad Ahmad
A1 Vilmantas Giedraitis
A1 Mercè Boada
A1 Dag Aarsland
A1 Pablo García-González
A1 Carla Abdelnour
A1 Emilio Alarcón-Martín
A1 Montserrat Alegret
A1 Ignacio Alvarez
A1 Victoria Álvarez
A1 Nicola J. Armstrong
A1 Anthoula Tsolaki
A1 Carmen Antúnez
A1 Ildebrando Appollonio
A1 Marina Arcaro
A1 Silvana Archetti
A1 Alfonso Arias Pastor
A1 Beatrice Arosio
A1 Lavinia Athanasiu
A1 Henri Bailly
A1 Nerisa Banaj
A1 Miquel Baquero
A1 Ana Belén Pastor
A1 Luisa Benussi
A1 Claudine Berr
A1 Céline Besse
A1 Valentina Bessi
A1 Giuliano Binetti
A1 Alessandra Bizzarro
A1 Daniel Alcolea
A1 Rafael Blesa
A1 Barbara Borroni
A1 Silvia Boschi
A1 Paola Bossù
A1 Geir Bråthen
A1 Catherine Bresner
A1 Keeley J. Brookes
A1 Luis Ignacio Brusco
A1 Katharina Bûrger
A1 María J. Bullido
A1 Vanessa Burholt
A1 William S. Bush
A1 Miguel Calero
A1 Carole Dufouil
A1 Ángel Carracedo
A1 Roberta Cecchetti
A1 Laura Cervera-Carles
A1 Camille Charbonnier
A1 Caterina Chillotti
A1 Henry Brodaty
A1 Simona Ciccone
A1 Jurgen A.H.R. Claassen
A1 Christopher Clark
A1 Elisa Conti
A1 Anaïs Corma-Gómez
A1 Emanuele Costantini
A1 Carlo Custodero
A1 Delphine Daian
A1 Maria Carolina Dalmasso
A1 Antonio Daniele
A1 Efthimios Dardiotis
A1 Jean-François Dartigues
A1 Peter Paul de Deyn
A1 Katia de Paiva Lopes
A1 Lot D. de Witte
A1 Stéphanie Debette
A1 Jürgen Deckert
A1 Teodoro del Ser
A1 Nicola Denning
A1 Anita DeStefano
A1 Martin Dichgans
A1 Janine Diehl-Schmid
A1 Mónica Diez-Fairen
A1 Paolo Dionigi Rossi
A1 Srdjan Djurovic
A1 Emmanuelle Duron
A1 Emrah Düzel
A1 Sebastiaan Engelborghs
A1 Valentina Escott-Price
A1 Ana Espinosa
A1 Dolores Buiza-Rueda
A1 Michael Ewers
A1 Fabrizio Tagliavini
A1 Sune Fallgaard Nielsen
A1 Lucia Farotti
A1 Chiara Fenoglio
A1 Marta Fernández-Fuertes
A1 John Hardy
A1 Raffaele Ferrari
A1 Catarina B Ferreira
A1 Evelyn Ferri
A1 Bertrand Fin
A1 Peter Fischer
A1 Tormod Fladby
A1 Klaus Fließbach
A1 Juan Fortea
A1 Silvia Fostinelli
A1 Nick C. Fox
A1 Emlio Franco-Macías
A1 Ana Frank-García
A1 Lutz Froelich
A1 Daniela Galimberti
A1 Jose Maria García-Alberca
A1 Sebastian Garcia-Madrona
A1 Guillermo García-Ribas
A1 Geneviève Chene
A1 Roberta Ghidoni
A1 Ina Giegling
A1 Giorgio Giaccone
A1 Oliver Goldhardt
A1 Antonio González-Pérez
A1 Caroline Graff
A1 Giulia Grande
A1 Emma Green
A1 Timo Grimmer
A1 Edna Grünblatt
A1 Tamar Guetta-Baranes
A1 Annakaisa Haapasalo
A1 Georgios Hadjigeorgiou
A1 Jonathan L. Haines
A1 Kara L. Hamilton-Nelson
A1 EADB
A1 Gra@ce
A1 ADGC
A1 Charge
A1 DemGen
A1 FinnGen
A1 EADI
A1 GERAD
A1 Harald Hampel
A1 Olivier Hanon
A1 Annette M. Hartmann
A1 Lucrezia Hausner
A1 Janet Harwood
A1 Stefanie Heilmann-Heimbach
A1 Seppo Helisalmi
A1 Michael T. Heneka
A1 Isabel Hernández
A1 Martin J. Herrmann
A1 Per Hoffmann
A1 Clive Holmes
A1 Henne Holstege
A1 Raquel Huerto Vilas
A1 Marc Hulsman
A1 Jack Humphrey
A1 Geert Jan Biessels
A1 Charlotte Johansson
A1 Patrick G. Kehoe
A1 Lena Kilander
A1 Anne Kinhult Ståhlbom
A1 Miia Kivipelto
A1 Anne Koivisto
A1 Johannes Kornhuber
A1 Mary H. Kosmidis
A1 Pavel P. Kuksa
A1 Brian W. Kunkle
A1 Carmen Lage
A1 Erika J Laukka
A1 Alessandra Lauria
A1 Chien-Yueh Lee
A1 Jenni Lehtisalo
A1 Claudia L. Satizabal
A1 Ondrej Lerch
A1 Alberto Lleó
A1 Rogelio Lopez
A1 Oscar Lopez
A1 Adolfo Lopez de Munain
A1 Seth Love
A1 Malin Löwemark
A1 Lauren Luckcuck
A1 Juan Macías
A1 Catherine A. MacLeod
A1 Wolfgang Maier
A1 Francesca Mangialasche
A1 Marco Spallazzi
A1 Marta Marquié
A1 Rachel Marshall
A1 Eden R. Martin
A1 Angel Martín Montes
A1 Carmen Martínez Rodríguez
A1 Carlo Masullo
A1 Richard Mayeux
A1 Simon Mead
A1 Patrizia Mecocci
A1 Miguel Medina
A1 Alun Meggy
A1 Silvia Mendoza
A1 Manuel Menéndez-González
A1 Pablo Mir
A1 Maria Teresa Periñán
A1 Merel Mol
A1 Laura Molina-Porcel
A1 Laura Montrreal
A1 Laura Morelli
A1 Fermín Moreno
A1 Kevin Morgan
A1 Markus M. Nöthen
A1 Carolina Muchnik
A1 Benedetta Nacmias
A1 Tiia Ngandu
A1 Gael Nicolas
A1 Børge G. Nordestgaard
A1 Robert Olaso
A1 Adelina Orellana
A1 Michela Orsini
A1 Gemma Ortega
A1 Alessandro Padovani
A1 Paolo Caffarra
A1 Goran Papenberg
A1 Lucilla Parnetti
A1 Florence Pasquier
A1 Pau Pastor
A1 Alba Pérez-Cordón
A1 Jordi Pérez-Tur
A1 Pierre Pericard
A1 Oliver Peters
A1 Yolande A.L. Pijnenburg
A1 Juan A Pineda
A1 Gerard Piñol-Ripoll
A1 Claudia Pisanu
A1 Thomas Polak
A1 Julius Popp
A1 Danielle Posthuma
A1 Josef Priller
A1 Raquel Puerta
A1 Olivier Quenez
A1 Inés Quintela
A1 Jesper Qvist Thomassen
A1 Alberto Rábano
A1 Innocenzo Rainero
A1 Inez Ramakers
A1 Luis M Real
A1 Marcel J.T. Reinders
A1 Steffi Riedel-Heller
A1 Peter Riederer
A1 Eloy Rodriguez-Rodriguez
A1 Arvid Rongve
A1 Irene Rosas Allende
A1 Maitée Rosende-Roca
A1 Jose Luis Royo
A1 Elisa Rubino
A1 Dan Rujescu
A1 María Eugenia Sáez
A1 Paraskevi Sakka
A1 Ingvild Saltvedt
A1 Ángela Sanabria
A1 María Bernal Sánchez-Arjona
A1 Florentino Sanchez-Garcia
A1 Shima Mehrabian
A1 Pascual Sánchez-Juan
A1 Raquel Sánchez-Valle
A1 Sigrid B Sando
A1 Michela Scamosci
A1 Nikolaos Scarmeas
A1 Elio Scarpini
A1 Philip Scheltens
A1 Norbert Scherbaum
A1 Martin Scherer
A1 Matthias Schmid
A1 Anja Schneider
A1 Jonathan M. Schott
A1 Geir Selbæk
A1 Jin Sha
A1 Alexey A Shadrin
A1 Olivia Skrobot
A1 Gijsje J. L. Snijders
A1 Hilkka Soininen
A1 Vincenzo Solfrizzi
A1 Alina Solomon
A1 Sandro Sorbi
A1 Oscar Sotolongo-Grau
A1 Gianfranco Spalletta
A1 Annika Spottke
A1 Alessio Squassina
A1 Juan Pablo Tartari
A1 Lluís Tárraga
A1 Niccolo Tesí
A1 Anbupalam Thalamuthu
A1 Thomas Tegos
A1 Latchezar Traykov
A1 Lucio Tremolizzo
A1 Anne Tybjærg-Hansen
A1 Andre Uitterlinden
A1 Abbe Ullgren
A1 Ingun Ulstein
A1 Sergi Valero
A1 Christine Van Broeckhoven
A1 Aad van der Lugt
A1 Jasper Van Dongen
A1 Jeroen van Rooij
A1 John van Swieten
A1 Rik Vandenberghe
A1 Frans Verhey
A1 Jean-Sébastien Vidal
A1 Jonathan Vogelgsang
A1 Martin Vyhnalek
A1 Michael Wagner
A1 David Wallon
A1 Li-San Wang
A1 Ruiqi Wang
A1 Leonie Weinhold
A1 Jens Wiltfang
A1 Gill Windle
A1 Bob Woods
A1 Mary Yannakoulia
A1 Yi Zhao
A1 Miren Zulaica
A1 Manuel Serrano-Rios
A1 Davide Seripa
A1 Eystein Stordal
A1 Lindsay A. Farrer
A1 Bruce M. Psaty
A1 Mohsen Ghanbari
A1 Towfique Raj
A1 Perminder Sachdev
A1 Karen Mather
A1 Frank Jessen
A1 M. Arfan Ikram
A1 Alexandre de Mendonça
A1 Jakub Hort
A1 Magda Tsolaki
A1 Margaret A. Pericak-Vance
A1 Philippe Amouyel
A1 Julie Williams
A1 Ruth Frikke-Schmidt
A1 Jordi Clarimon
A1 Jean-François Deleuze
A1 Giacomina Rossi
A1 Sudha Seshadri
A1 Ole A. Andreassen
A1 Martin Ingelsson
A1 Mikko Hiltunen
A1 Kristel Sleegers
A1 Gerard D. Schellenberg
A1 Cornelia M. van Duijn
A1 Rebecca Sims
A1 Wiesje M. van der Flier
A1 Agustín Ruiz
A1 Alfredo Ramirez
A1 Jean-Charles Lambert
YR 2020
UL http://medrxiv.org/content/early/2020/12/14/2020.10.01.20200659.abstract
AB Alzheimer’s disease (AD) is a severe and incurable neurodegenerative disease, and the failure to find effective treatments suggests that the underlying pathology remains poorly understood. Due to its strong heritability, deciphering the genetic landscape of AD and related dementia (ADD) is a unique opportunity to advance our knowledge. We completed a meta-analysis of genome-wide association studies (39,106 clinically AD-diagnosed cases, 46,828 proxy-ADD cases and 401,577 controls) with the most promising signals followed-up in 25,392 independent AD cases and 276,086 controls. We report 75 risk loci for ADD, including 42 novel ones. Pathway-enrichment analyses confirm the involvement of amyloid/Tau pathways, highlight the role of microglia and its potential interaction with APP metabolism. Numerous genes exhibited differential expression or splicing in AD-related conditions and gene prioritization implies EGFR signaling and TNF-α pathway through LUBAC complex. We also generated a novel polygenic risk score strongly associated with the risk of future dementia or progression from mild cognitive impairment to dementia. In conclusion, by more than doubling the number of loci associated with ADD risk, our study offers new insights into the pathophysiological processes underlying AD and offers additional therapeutic entry-points and tools for translational genomics.Competing Interest StatementHH is an employee of Eisai Inc. This work has been performed during his previous position at Sorbonne University, Paris, France. At Sorbonne University HH was supported by the AXA Research Fund, the Fondation partenariale Sorbonne University and the Fondation pour la Recherche sur Alzheimer, Paris, France.Funding StatementThis work was supported by a grant (European Alzheimer DNA BioBank, EADB) from the EU Joint Programme, Neurodegenerative Disease Research (JPND). Inserm UMR1167 is also funded by Inserm, Institut Pasteur de Lille, the Lille Metropole Communaute Urbaine, the French government LABEX DISTALZ program (development of innovative strategies for a transdisciplinary approach to Alzheimer disease). Additional support for EADB cohorts was provided by: Italian Ministry of Health (Ricerca Corrente); Ministero dell Istruzione, dell Universita e della RicercaMIUR project Dipartimenti di Eccellenza 2018 2022 to Department of Neuroscience Rita Levi Montalcini, University of Torino (IR), and AIRAlzh Onlus ANCCCOOP (SB); Partly supported by Ministero della Salute, I.R.C.C.S. Research Program, Ricerca Corrente 2018 2020, Linea n. 2 Meccanismi genetici, predizione e terapie innovative delle malattie complesse and by the 5 x 1000 voluntary contribution to the Fondazione I.R.C.C.S. Ospedale Casa Sollievo della Sofferenza; and RF 2018 12366665, Fondi per la ricerca 2019 (Sandro Sorbi). Copenhagen General Population Study (CGPS): We thank staff and participants of the CGPS for their important contributions. Karolinska Institutet AD cohort: Dr. Graff and coauthors of the Karolinska Institutet AD cohort report grants from Swedish Research Council (VR) 2015 02926, 2018 02754, 2015 06799, Swedish Alzheimer Foundation, Stockholm County Council ALF and research school, Karolinska Institutet StratNeuro, Swedish Demensfonden, and Swedish brain foundation, during the conduct of the study. ADGEN: This work was supported by Academy of Finland (grant numbers 307866); Sigrid Juselius Foundation; the Strategic Neuroscience Funding of the University of Eastern Finland; EADB project in the JPNDCOFUND program (grant number 301220). CBAS: Supported by the project no. LQ1605 from the National Program of Sustainability II (MEYS CR), Supported by Ministry of Health of the Czech Republic, grant nr. NV190400270 (All rights reserved), Grant Agency of Charles University Grants No. 693018 and 654217; the Ministry of Health, Czech Republic―conceptual development of research organization, University Hospital Motol, Prague, Czech Republic Grant No. 00064203; the Czech Ministry of Health Project AZV Grant No. 16―27611A; and Institutional Support of Excellence 2. LF UK Grant No. 699012. CNRMAJRouen: This study received fundings from the Centre National de Rfrence Malades Alzheimer Jeunes (CNRMAJ). The Finnish Geriatric Intervention Study for the Prevention of Cognitive Impairment and Disability (FINGER) data collection was supported by grants from the Academy of Finland, La Carita Foundation, Juho Vainio Foundation, Novo Nordisk Foundation, Finnish Social Insurance Institution, Ministry of Education and Culture Research Grants, Yrjo Jahnsson Foundation, Finnish Cultural Foundation South Osthrobothnia Regional Fund, and EVO/State Research Funding grants of University Hospitals of Kuopio, Oulu and Turku, Seinajoki Central Hospital and Oulu City Hospital, Alzheimer Research & Prevention Foundation USA, AXA Research Fund, Knut and Alice Wallenberg Foundation Sweden, Center for Innovative Medicine (CIMED) at Karolinska Institutet Sweden, and Stiftelsen Stockholms sjukhem Sweden. FINGER cohort genotyping was funded by EADB project in the JPND COFUND (grant number 301220). Research on the Belgian EADB cohort is funded in part by the Alzheimer Research Foundation (SAOFRA), The Research Foundation Flanders (FWO), and the University of Antwerp Research Fund. FK is supported by a BOF DOCPRO fellowship of the University of Antwerp Research Fund. SNACK is financially supported by the Swedish Ministry of Health and Social Affairs, the participating County Councils and Municipalities, and the Swedish Research Council. BDR Bristol: We would like to thank the South West Dementia Brain Bank (SWDBB) for providing brain tissue for this study. The SWDBB is part of the Brains for Dementia Research programme, jointly funded by Alzheimers Research UK and Alzheimer Society and is supported by BRACE (Bristol Research into Alzheimers and Care of the Elderly) and the Medical Research Council. BDR Manchester: We would like to thank the Manchester Brain Bank for providing brain tissue for this study. The Manchester Brain Bank is part of the Brains for Dementia Research programme, jointly funded by Alzheimers Research UK and Alzheimers Society. BDR KCL: Human postmortem tissue was provided by the London Neurodegenerative Diseases Brain Bank which receives funding from the UK Medical Research Council and as part of the Brains for Dementia Research programme, jointly funded by Alzheimer Research UK and the Alzheimers Society. The CFAS Wales study was funded by the ESRC (RES060250060) and HEFCW as Maintaining function and wellbeing in later life: a longitudinal cohort study, (Principal Investigators: R.T Woods, L.Clare, G.Windle, V. Burholt, J. Philips, C. Brayne, C. McCracken, K. Bennett, F. Matthews). MRC: Cardiff University was supported by the Alzheimer Society (AS; grant RF014/164) and the Medical Research Council (MRC; grants G0801418/1, MR/K013041/1, MR/L023784/1) (R. Sims is an AS Research Fellow). Cardiff University was also supported by the European Joint Programme for Neurodegenerative Disease (JPND; grant MR/L501517/1), Alzheimer Research UK (ARUK; grant ARUKPG20141), the Welsh Assembly Government (grant SGR544:CADR), Brain for dementia Research and a donation from the Moondance Charitable Foundation. Patient recruitment for the MRC Prion Unit/UCL Department of Neurodegenerative Disease collection was supported by the UCLH/UCL Biomedical Centre and NIHR Queen Square Dementia Biomedical Research Unit. The University of Southampton acknowledges support from the AS. King College London was supported by the NIHR Biomedical Research Centre for Mental Health and the Biomedical Research Unit for Dementia at the South London and Maudsley NHS Foundation Trust and by King College London and the MRC. ARUK and the Big Lottery Fund provided support to Nottingham University. Alfredo Ramirez: Part of the work was funded by the JPND EADB grant (German Federal Ministry of Education and Research (BMBF) grant: 01ED1619A). German Study on Ageing, Cognition and Dementia in Primary Care Patients (AgeCoDe): This study/publication is part of the German Research Network on Dementia (KND), the German Research Network on Degenerative Dementia (KNDD; German Study on Ageing, Cognition and Dementia in Primary Care Patients; AgeCoDe), and the Health Service Research Initiative (Study on Needs, health service use, costs and healthrelated quality of life in a large sample of oldestold primary care patients (85+; AgeQualiDe)) and was funded by the German Federal Ministry of Education and Research (grants KND: 01GI0102, 01GI0420, 01GI0422, 01GI0423, 01GI0429, 01GI0431, 01GI0433, 01GI0434; grants KNDD: 01GI0710, 01GI0711, 01GI0712, 01GI0713, 01GI0714, 01GI0715, 01GI0716; grants Health Service Research Initiative: 01GY1322A, 01GY1322B, 01GY1322C, 01GY1322D, 01GY1322E, 01GY1322F, 01GY1322G). VITA study: The support of the Ludwig Boltzmann Society and the AFI Germany have supported the VITA study. This work was financed by a research grant of the Vogelstiftung Dr. Eckernkamp. HELIAD study: This study was supported by the grants: IIRG09133014 from the Alzheimer Association, 189 10276/8/9/2011 from the ESPAEU program Excellence Grant (ARISTEIA) and the 51657/14.4.2009 of the Ministry for Health and Social Solidarity (Greece). Biobank Department of Psychiatry, UMG: Prof. Jens Wiltfang is supported by an Ildio Pinho professorship and iBiMED (UID/BIM/04501/2013), and FCT project PTDC/DTP_PIC/5587/2014 at the University of Aveiro, Portugal. Lausanne study: This work was supported by grants from the Swiss National Research Foundation (SNF 320030_141179). PAGES study: Harald Hampel is an employee of Eisai Inc. During part of this work he was supported by the AXA Research Fund, the Fondation partenariale Sorbonne Universit and the Fondation pour la Recherche sur Alzheimer, Paris, France. Mannheim, Germany Biobank: Department of geriatric Psychiatry, Central Institute for Mental Health, Mannheim, University of Heidelberg, Germany. Genotyping for the Swedish Twin Studies of Aging was supported by NIH/NIA grant R01 AG037985. Genotyping in TwinGene was supported by NIH/NIDDK U01 DK066134. WvdF is recipient of Joint Programming for Neurodegenerative Diseases (JPND) grants PERADES (ANR13JPRF0001) and EADB (733051061). Gothenburg Birth Cohort (GBC) Studies: We would like to thank UCL Genomics for performing the genotyping analyses. The studies were supported by The Stena Foundation, The Swedish Research Council (201502830, 20138717), The Swedish Research Council for Health, Working Life and Wellfare (20131202, 20050762, 20081210, 20132300, 2013 2496, 20130475), The Brain Foundation, Sahlgrenska University Hospital (ALF), The Alzheimer Association (IIRG036168), The Alzheimers Association Zenith Award (ZEN013151), Eivind och Elsa K:son Sylvans Stiftelse, The Swedish Alzheimer Foundation. Clinical AD, Sweden: We would like to thank UCL Genomics for performing the genotyping analyses. Barcelona Brain Biobank: Brain Donors of the Neurological Tissue Bank of the BiobancHospital ClinicIDIBAPS and their families for their generosity. Hospital Clnic de Barcelona Spanish Ministry of Economy and CompetitivenessInstituto de Salud Carlos III and Fondo Europeo de Desarrollo Regional (FEDER), Union Europea, Una manera de hacer Europa grants (PI16/0235 to Dr. R. SanchezValle and PI17/00670 to Dr. A.Antonell). AA is funded by Departament de Salut de la Generalitat de Catalunya, PERIS 20162020 (SLT002/16/00329). Sydney Memory and Ageing Study (Sydney MAS): We gratefully acknowledge and thank the following for their contributions to Sydney MAS: participants, their supporters and the Sydney MAS Research Team (current and former staff and students). Funding was awarded from the Australian National Health and Medical Research Council (NHMRC) Program Grants (350833, 568969, 109308). AddNeuroMed consortium was led by Simon Lovestone, Bruno Vellas, Patrizia Mecocci, Magda Tsolaki, Iwona Kłoszewska, Hilkka Soininen. This work was supported by InnoMed (Innovative Medicines in Europe), an integrated project funded by the European Union of the Sixth Framework program priority (FP62004 LIFESCIHEALTH5). Oviedo: This work was partly supported by Grant from Fondo de Investigaciones SanitariasFondos FEDER EuropeanUnion to Victoria Alvarez PI15/00878. Pascual SanchezJuan is supported by CIBERNED and Carlos III Institute of Health, Spain (PI08/0139, PI12/02288, and PI16/01652), jointly funded by Fondo Europeo de Desarrollo Regional (FEDER), Union Europea, Una manera de hacer Europa. Project MinE: The ProjectMinE study was supported by the ALS Foundation Netherlands and the MND association (UK) (Project MinE, www.projectmine.com). The SPIN cohort: We are indebted to patients and their families for their participation in the Sant Pau Initiative on Neurodegeneration cohort, at the Sant Pau Hospital (Barcelona). This is a multimodal research cohort for biomarker discovery and validation that is partially funded by Generalitat de Catalunya (2017 SGR 547 to JC), as well as from the Institute of Health Carlos IIISubdireccion General de Evaluacion and the Fondo Europeo de Desarrollo Regional (FEDER Una manera de Hacer Europa) (grants PI11/02526, PI14/01126, and PI17/01019 to JF; PI17/01895 to AL), and the Centro de Investigacion Biomdica en Red Enfermedades Neurodegenerativas programme (Program 1, Alzheimer Disease to AL). We would also like to thank the Fundacio Bancaria Obra Social La Caixa (DABNI project) to JF and AL; and Fundacion BBVA (to AL), for their support in funding this followup study. Adolfo Lopez de Munain is supported by Fundacion Salud 2000 (PI2013156) and Diputacion Foral de Gipuzkoa (Exp.114/17). Grace. The Genome Research @ Fundacio ACE project (GR@ACE) is supported by Grifols SA, Fundacion bancaria La Caixa, Fundacio ACE, and CIBERNED. A.R. and M.B. receive support from the European Union/EFPIA Innovative Medicines Initiative Joint undertaking ADAPTED and MOPEAD projects (grant numbers 115975 and 115985, respectively). M.B. and A.R. are also supported by national grants PI13/02434, PI16/01861, PI17/01474 and PI19/01240. Accion Estratgica en Salud is integrated into the Spanish National R + D + I Plan and funded by ISCIII (Instituto de Salud Carlos III)Subdireccion General de Evaluacion and the Fondo Europeo de Desarrollo Regional (FEDERUna manera de hacer Europa). Some control samples and data from patients included in this study were provided in part by the National DNA Bank Carlos III (www.bancoadn.org, University of Salamanca, Spain) and Hospital Universitario Virgen de Valme (Sevilla, Spain); they were processed following standard operating procedures with the appropriate approval of the Ethical and Scientific Committee. The present work has been performed as part of the doctoral program of I. de Rojas at the Universitat de Barcelona (Barcelona, Spain). EADI. This work has been developed and supported by the LABEX (laboratory of excellence program investment for the future) DISTALZ grant (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimers disease) including funding from MEL (Metropole europenne de Lille), ERDF (European Regional Development Fund) and Conseil Rgional Nord Pas de Calais. This work was supported by INSERM, the National Foundation for Alzheimers disease and related disorders, the Institut Pasteur de Lille and the Centre National de Recherche en Gnomique Humaine, CEA, the JPND PERADES, the Laboratory of Excellence GENMED (Medical Genomics) grant no. ANR10LABX0013 managed by the National Research Agency (ANR) part of the Investment for the Future program, and the FP7 AgedBrainSysBio. The ThreeCity Study was performed as part of collaboration between the Institut National de la Sant et de la Recherche Mdicale (Inserm), the Victor Segalen Bordeaux II University and SanofiSynthlabo. The Fondation pour la Recherche Mdicale funded the preparation and initiation of the study. The 3C Study was also funded by the Caisse Nationale Maladie des Travailleurs Salaris, Direction Gnrale de la Sant, MGEN, Institut de la Longvit, Agence Francaise de Scurit Sanitaire des Produits de Sant, the Aquitaine and Bourgogne Regional Councils, Agence Nationale de la Recherche, ANR supported the COGINUT and COVADIS projects. Fondation de France and the joint French Ministry of Research/INSERM Cohortes et collections de donnes biologiques programme. Lille Gnopole received an unconditional grant from Eisai. The Threecity biological bank was developed and maintained by the laboratory for genomic analysis LAGBRC Institut Pasteur de Lille. GERAD/PERADES. We thank all individuals who participated in this study. Cardiff University was supported by the Wellcome Trust, Alzheimers Society (AS; grant RF014/164), the Medical Research Council (MRC; grants G0801418/1, MR/K013041/1, MR/L023784/1), the European Joint Programme for Neurodegenerative Disease (JPND, grant MR/L501517/1), Alzheimers Research UK (ARUK, grant ARUKPG20141), Welsh Assembly Government (grant SGR544:CADR), a donation from the Moondance Charitable Foundation, UK Dementias Platform (DPUK, reference MR/L023784/1), and the UK Dementia Research Institute at Cardiff. Cambridge University acknowledges support from the MRC. ARUK supported sample collections at the Kings College London, the South West Dementia Bank, Universities of Cambridge, Nottingham, Manchester and Belfast. Kings College London was supported by the NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at the South London and Maudsley NHS Foundation Trust and Kings College London and the MRC. Alzheimers Research UK (ARUK) and the Big Lottery Fund provided support to Nottingham University. Ulster Garden Villages, AS, ARUK, American Federation for Aging Research, NI R&D Office and the Royal College of Physicians/Dunhill Medical Trust provided support for Queens University, Belfast. The University of Southampton acknowledges support from the AS. The MRC and Mercers Institute for Research on Ageing supported the Trinity College group. DCR is a Wellcome Trust Principal Research fellow. The South West Dementia Brain Bank acknowledges support from Bristol Research into Alzheimers and Care of the Elderly. The Charles Wolfson Charitable Trust supported the OPTIMA group. Washington University was funded by NIH grants, Barnes Jewish Foundation and the Charles and Joanne Knight Alzheimers Research Initiative. Patient recruitment for the MRC Prion Unit/UCL Department of Neurodegenerative Disease collection was supported by the UCLH/UCL Biomedical Research Centre and their work was supported by the NIHR Queen Square Dementia BRU, the Alzheimers Research UK and the Alzheimers Society. LASERAD was funded by Lundbeck SA. The AgeCoDe study group was supported by the German Federal Ministry for Education and Research grants 01 GI 0710, 01 GI 0712, 01 GI 0713, 01 GI 0714, 01 GI 0715, 01 GI 0716, 01 GI 0717. Genotyping of the Bonn casecontrol sample was funded by the German centre for Neurodegenerative Diseases (DZNE), Germany. The GERAD Consortium also used samples ascertained by the NIMH AD Genetics Initiative. HH was supported by a grant of the KatharinaHardtFoundation, Bad Homburg vor der Hohe, Germany. The KORA F4 studies were financed by Helmholtz Zentrum Munchen; German Research Center for Environmental Health; BMBF; German National Genome Research Network and the Munich Center of Health Sciences. The Heinz Nixdorf Recall cohort was funded by the Heinz Nixdorf Foundation (Dr. Jur. G.Schmidt, Chairman) and BMBF. We acknowledge use of genotype data from the 1958 Birth Cohort collection and National Blood Service, funded by the MRC and the Wellcome Trust which was genotyped by the Wellcome Trust Case Control Consortium and the Type1 Diabetes Genetics Consortium, sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Allergy and Infectious Diseases, National Human Genome Research Institute, National Institute of Child Health and Human Development and Juvenile Diabetes Research Foundation International. The project is also supported through the following funding organisations under the aegis of JPND www.jpnd.eu (United Kingdom, Medical Research Council (MR/L501529/1; MR/R024804/1) and Economic and Social Research Council (ES/L008238/1)) and through the Motor Neurone Disease Association. This study represents independent research part funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and Kings College London. Prof Jens Wiltfang is supported by an Ildio Pinho professorship and iBiMED (UID/BIM/04501/2013), at the University of Aveiro, Portugal. Rotterdam study. Rotterdam (RS). This study was funded by the Netherlands Organisation for Health Research and Development (ZonMW) as part of the Joint Programming for Neurological Disease (JPND)as part of the PERADES Program (Defining Genetic Polygenic, and Environmental Risk for Alzheimers disease using multiple powerful cohorts, focused Epigenetics and Stem cell metabolomics), Project number 733051021. This work was funded also by the European Union Innovative Medicine Initiative (IMI) programme under grant agreement No. 115975 as part of the Alzheimers Disease Apolipoprotein Pathology for Treatment Elucidation and Development (ADAPTED, https://www.imiadapted.eu);and the European Unions Horizon 2020 research and innovation programme as part of the Common mechanisms and pathways in Stroke and Alzheimers disease CoSTREAM project (www.costream.eu, grant agreement No. 667375). The current study is supported by the Deltaplan Dementie and Memorabel supported by ZonMW (Project number 733050814) and Alzheimer Nederland. The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. The authors are grateful to the study participants, the staff from the Rotterdam Study and the participating general practitioners and pharmacists. The generation and management of GWAS genotype data for the Rotterdam Study (RSI, RSII, RSIII) was executed by the Human Genotyping Facility of the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands. The GWAS datasets are supported by the Netherlands Organization of Scientific Research NWO Investments (Project number 175.010.2005.011, 91103012), the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, the Research Institute for Diseases in the Elderly (01493015; RIDE2), the Netherlands Genomics Initiative (NGI)/Netherlands Organization for Scientific Research (NWO) Netherlands Consortium for Healthy Aging (NCHA), project number 050060810. We thank Pascal Arp, Mila Jhamai, Marijn Verkerk, Lizbeth Herrera and Marjolein Peters, MSc, and Carolina MedinaGomez, MSc, for their help in creating the GWAS database, and Karol Estrada, PhD, Yurii Aulchenko, PhD, and Carolina Medina Gomez, MSc, for the creation and analysis of imputed data. DemGene. The project has received funding from The Research Council of Norway (RCN) Grant Nos. 213837, 223273, 225989, 248778, and 251134 and EU JPND Program ApGeM RCN Grant No. 237250, the SouthEast Norway Health Authority Grant No. 2013123, the Norwegian Health Association, and KG Jebsen Foundation. The RCN FRIPRO Mobility grant scheme (FRICON) is cofunded by the European Unions Seventh Framework Programme for research, technological development and demonstration under Marie Curie grant agreement No 608695. European Communitys grant PIAPPGA2011286213 PsychDPC. Bonn study. This group would like to thank Dr. Heike Koelsch for her scientific support. The Bonn group was funded by the German Federal Ministry of Education and Research (BMBF): Competence Network Dementia (CND) grant number 01GI0102, 01GI0711, 01GI042 ADGC. The National Institutes of Health, National Institute on Aging (NIHNIA) supported this work through the following grants: ADGC, U01 AG032984, RC2 AG036528; Samples from the National Cell Repository for Alzheimers Disease (NCRAD), which receives government support under a cooperative agreement grant (U24 AG21886) awarded by the National Institute on Aging (NIA), were used in this study. We thank contributors who collected samples used in this study, as well as patients and their families, whose help and participation made this work possible; Data for this study were prepared, archived, and distributed by the National Institute on Aging Alzheimers Disease Data Storage Site (NIAGADS) at the University of Pennsylvania (U24AG04168901); NACC, U01 AG016976; NIA LOAD (Columbia University), U24 AG026395, U24 AG026390, R01AG041797; Banner Sun Health Research Institute P30 AG019610; Boston University, P30 AG013846, U01 AG10483, R01 CA129769, R01 MH080295, R01 AG017173, R01 AG025259, R01 AG048927, R01AG33193, R01 AG009029; Columbia University, P50 AG008702, R37 AG015473, R01 AG037212, R01 AG028786; Duke University, P30 AG028377, AG05128; Einstein Aging Study NIA grant at Albert Einstein College of Medicine, P01 AG03949. Emory University, AG025688; Group Health Research Institute, UO1 AG006781, UO1 HG004610, UO1 HG006375, U01 HG008657; Indiana University, P30 AG10133, R01 AG009956, RC2 AG036650; Johns Hopkins University, P50 AG005146, R01 AG020688; Massachusetts General Hospital, P50 AG005134; Mayo Clinic, P50 AG016574, R01 AG032990, KL2 RR024151; Mount Sinai School of Medicine, P50 AG005138, P01 AG002219; New York University, P30 AG08051, UL1 RR029893, 5R01AG012101, 5R01AG022374, 5R01AG013616, 1RC2AG036502, 1R01AG035137; North Carolina A&T University, P20 MD000546, R01 AG2878601A1; Northwestern University, P30 AG013854; Oregon Health & Science University, P30 AG008017, R01 AG026916; Rush University, P30 AG010161, R01 AG019085, R01 AG15819, R01 AG17917, R01 AG030146, R01 AG01101, RC2 AG036650, R01 AG22018; TGen, R01 NS059873; University of Alabama at Birmingham, P50 AG016582; University of Arizona, R01 AG031581; University of California, Davis, P30 AG010129; University of California, Irvine, P50 AG016573; University of California, Los Angeles, P50 AG016570; University of California, San Diego, P50 AG005131; University of California, San Francisco, P50 AG023501, P01 AG019724; University of Kentucky, P30 AG028383, AG05144; University of Michigan, P30 AG053760 and AG063760; University of Pennsylvania, P30 AG010124; University of Pittsburgh, P50 AG005133, AG030653, AG041718, AG07562, AG02365; University of Southern California, P50 AG005142; University of Texas Southwestern, P30 AG012300; University of Miami, R01 AG027944, AG010491, AG027944, AG021547, AG019757; University of Washington, P50 AG005136, R01 AG042437; University of Wisconsin, P50 AG033514; Vanderbilt University, R01 AG019085; and Washington University, P50 AG005681, P01 AG03991, P01 AG026276. HP was supported by AG025711. ER was supported by CCNA. The Kathleen Price Bryan Brain Bank at Duke University Medical Center is funded by NINDS grant # NS39764, NIMH MH60451 and by Glaxo Smith Kline. Support was also from the Alzheimers Association (LAF, IIRG0889720; MPV, IIRG05 14147), the US Department of Veterans Affairs Administration, Office of Research and Development, Biomedical Laboratory Research Program, and BrightFocus Foundation (MPV, A2111048). P.S.G.H. is supported by Wellcome Trust, Howard Hughes Medical Institute, and the Canadian Institute of Health Research. Genotyping of the TGEN2 cohort was supported by Kronos Science. The TGen series was also funded by NIA grant AG041232 to AJM and MJH, The Banner Alzheimers Foundation, The Johnnie B. Byrd Sr. Alzheimers Institute, the Medical Research Council, and the state of Arizona and also includes samples from the following sites: Newcastle Brain Tissue Resource (funding via the Medical Research Council, local NHS trusts and Newcastle University), MRC London Brain Bank for Neurodegenerative Diseases (funding via the Medical Research Council),South West Dementia Brain Bank (funding via numerous sources including the Higher Education Funding Council for England (HEFCE), Alzheimers Research Trust (ART), BRACE as well as North Bristol NHS Trust Research and Innovation department and DeNDRoN), The Netherlands Brain Bank (funding via numerous sources including Stichting MS Research, Brain Net Europe, Hersenstichting Nederland Breinbrekend Werk, International Parkinson Fonds, Internationale Stiching Alzheimer Onderzoek), Institut de Neuropatologia, Servei Anatomia Patologica, Universitat de Barcelona. ADNI data collection and sharing was funded by the National Institutes of Health Grant U01 AG024904 and Department of Defense award number W81XWH1220012. ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimers Association; Alzheimers Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; BristolMyers Squibb Company; CereSpir, Inc.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. HoffmannLa Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimers Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. We thank Drs. D. Stephen Snyder and Marilyn Miller from NIA who are exofficio ADGC members. Charge. Cardiovascular Health Study (CHS). Cardiovascular Health Study: This CHS research was supported by NHLBI contracts HHSN268201200036C, HHSN268200800007C, HHSN268201800001C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086; and NHLBI grants U01HL080295, U01HL130114, R01HL087652, R01HL105756, R01HL103612,and R01HL120393 with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through R01AG023629, R01AG033193, R01AG15928, R01AG20098, and U01AG049505 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHSNHLBI.org. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR001881, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center. Framingham Heart Study. This work was supported by the National Heart, Lung, and Blood Institutes Framingham Heart Study (contracts N01HC25195 and HHSN268201500001I). This study was also supported by grants from the National Institute on Aging: R01AG033193, U01AG049505, U01AG52409, R01AG054076, RF1AG0059421 (S. Seshadri). S. Seshadri and A.L.D. were also supported by additional grants from the National Institute on Aging (R01AG049607, R01AG033040, RF1AG0061872, U01AG058589) and the National Institute of Neurological Disorders and Stroke (R01NS017950, NS100605). The content is solely the responsibility of the authors and does not necessarily represent the official views of the US National Institutes of Health. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Written informed consent was obtained from study participants or, for those with substantial cognitive impairment, from a caregiver, legal guardian or other proxy. Study protocols for all cohorts were reviewed and approved by the appropriate institutional review boards.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yessummary statistics will be made available followoing publication of the article